Lilly Presents Updated Data of Verzenio (abemaciclib) in P-III monarchE Trial Presented at ESMO and Published in the Annals of Oncology

Shots:

• The P-III monarchE trial assessed Verzenio (150mg, bid) + SOC vs SOC alone in patients with EBC in a ratio (1:1) for 2yrs. Patients in both treatment arms were instructed to continue to receive adjuvant ET for up to 5-10 years as recommended by their clinician
• In the updated analysis, the benefits of IDFS and DRFS were maintained. @3yrs; absolute improvement rates in IDFS and DRFS (5.4% and 4.2%). With additional follow up, the treatment benefit was maintained over time and extended beyond the 2yrs. treatment period
• Consistent Verzenio treatment benefit in reducing the risk of recurrence was observed in patients regardless of Ki-67 score

Click here to­ read the full press release/ article | Ref: Eli Lilly | Image: WRGB